Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behçet's disease and its association with disease activity

A pilot study

Eun Chun Han, Sung Bin Cho, Keun Jae Ahn, SangHo Oh, Jihyun Kim, Dong Soo Kim, Kwanghoon Lee, Dongsik Bang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: S100A12 is a member of the S100 family of calcium-binding proteins and is secreted either in inflamed tissues or in the bloodstream by activated neutrophils. Expression of S100A12 has been reported in various diseases, especially non-infectious inflammatory diseases, such as Kawasaki disease, giant cell arteritis and inflammatory bowel disease. Objective: This study was conducted to determine both the tissue expression and the serum levels of S100A12 in Behçet's disease (BD) patients and the correlation of the S100A12 serum level with disease activity of BD. Methods: We included in this study ten BD patients who fulfilled the criteria for diagnosis, according to the International Study Group for BD. The activity of BD was calculated using the BD Current Activity Form. The serum concentrations of both SI 00A12 and interleukin-8 were measured by the enzyme-linked immunosorbent assay, before and after treatment. Immunohistochemical studies were also performed to detect SI 00A12 expression in the skin. Results: The serum S100A12 level was significantly increased in the active BD period (p<0.001), in the inactive BD period (p = 0.041) and in patients with active Kawasaki disease (p = 0.028), compared with the serum level in the healthy controls. The serum S100A12 level decreased significantly from baseline, compared to post-treatment (p = 0.017). The activity score of BD was significantly correlated with the serum level of S100A12 (Spearman's coefficient = 0.464, p = 0.039). Immunohistochemical studies showed that S100A12 was strongly expressed in the erythema nodosum-like skin lesions of patients. Conclusion: S100A12 contributes to the pathogenesis of BD related to neutrophil hyperactivity and reflects the disease activity in BD patients.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalAnnals of Dermatology
Volume23
Issue number3
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

Serum
Mucocutaneous Lymph Node Syndrome
S100A12 Protein
Neutrophils
Erythema Nodosum
Skin
Giant Cell Arteritis
Calcium-Binding Proteins
Interleukin-8
Inflammatory Bowel Diseases
Enzyme-Linked Immunosorbent Assay
Therapeutics

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Han, Eun Chun ; Cho, Sung Bin ; Ahn, Keun Jae ; Oh, SangHo ; Kim, Jihyun ; Kim, Dong Soo ; Lee, Kwanghoon ; Bang, Dongsik. / Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behçet's disease and its association with disease activity : A pilot study. In: Annals of Dermatology. 2011 ; Vol. 23, No. 3. pp. 313-320.
@article{526beaa567a54e43b511f9ec383cd93c,
title = "Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Beh{\cc}et's disease and its association with disease activity: A pilot study",
abstract = "Background: S100A12 is a member of the S100 family of calcium-binding proteins and is secreted either in inflamed tissues or in the bloodstream by activated neutrophils. Expression of S100A12 has been reported in various diseases, especially non-infectious inflammatory diseases, such as Kawasaki disease, giant cell arteritis and inflammatory bowel disease. Objective: This study was conducted to determine both the tissue expression and the serum levels of S100A12 in Beh{\cc}et's disease (BD) patients and the correlation of the S100A12 serum level with disease activity of BD. Methods: We included in this study ten BD patients who fulfilled the criteria for diagnosis, according to the International Study Group for BD. The activity of BD was calculated using the BD Current Activity Form. The serum concentrations of both SI 00A12 and interleukin-8 were measured by the enzyme-linked immunosorbent assay, before and after treatment. Immunohistochemical studies were also performed to detect SI 00A12 expression in the skin. Results: The serum S100A12 level was significantly increased in the active BD period (p<0.001), in the inactive BD period (p = 0.041) and in patients with active Kawasaki disease (p = 0.028), compared with the serum level in the healthy controls. The serum S100A12 level decreased significantly from baseline, compared to post-treatment (p = 0.017). The activity score of BD was significantly correlated with the serum level of S100A12 (Spearman's coefficient = 0.464, p = 0.039). Immunohistochemical studies showed that S100A12 was strongly expressed in the erythema nodosum-like skin lesions of patients. Conclusion: S100A12 contributes to the pathogenesis of BD related to neutrophil hyperactivity and reflects the disease activity in BD patients.",
author = "Han, {Eun Chun} and Cho, {Sung Bin} and Ahn, {Keun Jae} and SangHo Oh and Jihyun Kim and Kim, {Dong Soo} and Kwanghoon Lee and Dongsik Bang",
year = "2011",
month = "8",
day = "1",
doi = "10.5021/ad.2011.23.3.313",
language = "English",
volume = "23",
pages = "313--320",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "3",

}

Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behçet's disease and its association with disease activity : A pilot study. / Han, Eun Chun; Cho, Sung Bin; Ahn, Keun Jae; Oh, SangHo; Kim, Jihyun; Kim, Dong Soo; Lee, Kwanghoon; Bang, Dongsik.

In: Annals of Dermatology, Vol. 23, No. 3, 01.08.2011, p. 313-320.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behçet's disease and its association with disease activity

T2 - A pilot study

AU - Han, Eun Chun

AU - Cho, Sung Bin

AU - Ahn, Keun Jae

AU - Oh, SangHo

AU - Kim, Jihyun

AU - Kim, Dong Soo

AU - Lee, Kwanghoon

AU - Bang, Dongsik

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background: S100A12 is a member of the S100 family of calcium-binding proteins and is secreted either in inflamed tissues or in the bloodstream by activated neutrophils. Expression of S100A12 has been reported in various diseases, especially non-infectious inflammatory diseases, such as Kawasaki disease, giant cell arteritis and inflammatory bowel disease. Objective: This study was conducted to determine both the tissue expression and the serum levels of S100A12 in Behçet's disease (BD) patients and the correlation of the S100A12 serum level with disease activity of BD. Methods: We included in this study ten BD patients who fulfilled the criteria for diagnosis, according to the International Study Group for BD. The activity of BD was calculated using the BD Current Activity Form. The serum concentrations of both SI 00A12 and interleukin-8 were measured by the enzyme-linked immunosorbent assay, before and after treatment. Immunohistochemical studies were also performed to detect SI 00A12 expression in the skin. Results: The serum S100A12 level was significantly increased in the active BD period (p<0.001), in the inactive BD period (p = 0.041) and in patients with active Kawasaki disease (p = 0.028), compared with the serum level in the healthy controls. The serum S100A12 level decreased significantly from baseline, compared to post-treatment (p = 0.017). The activity score of BD was significantly correlated with the serum level of S100A12 (Spearman's coefficient = 0.464, p = 0.039). Immunohistochemical studies showed that S100A12 was strongly expressed in the erythema nodosum-like skin lesions of patients. Conclusion: S100A12 contributes to the pathogenesis of BD related to neutrophil hyperactivity and reflects the disease activity in BD patients.

AB - Background: S100A12 is a member of the S100 family of calcium-binding proteins and is secreted either in inflamed tissues or in the bloodstream by activated neutrophils. Expression of S100A12 has been reported in various diseases, especially non-infectious inflammatory diseases, such as Kawasaki disease, giant cell arteritis and inflammatory bowel disease. Objective: This study was conducted to determine both the tissue expression and the serum levels of S100A12 in Behçet's disease (BD) patients and the correlation of the S100A12 serum level with disease activity of BD. Methods: We included in this study ten BD patients who fulfilled the criteria for diagnosis, according to the International Study Group for BD. The activity of BD was calculated using the BD Current Activity Form. The serum concentrations of both SI 00A12 and interleukin-8 were measured by the enzyme-linked immunosorbent assay, before and after treatment. Immunohistochemical studies were also performed to detect SI 00A12 expression in the skin. Results: The serum S100A12 level was significantly increased in the active BD period (p<0.001), in the inactive BD period (p = 0.041) and in patients with active Kawasaki disease (p = 0.028), compared with the serum level in the healthy controls. The serum S100A12 level decreased significantly from baseline, compared to post-treatment (p = 0.017). The activity score of BD was significantly correlated with the serum level of S100A12 (Spearman's coefficient = 0.464, p = 0.039). Immunohistochemical studies showed that S100A12 was strongly expressed in the erythema nodosum-like skin lesions of patients. Conclusion: S100A12 contributes to the pathogenesis of BD related to neutrophil hyperactivity and reflects the disease activity in BD patients.

UR - http://www.scopus.com/inward/record.url?scp=80052089457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052089457&partnerID=8YFLogxK

U2 - 10.5021/ad.2011.23.3.313

DO - 10.5021/ad.2011.23.3.313

M3 - Article

VL - 23

SP - 313

EP - 320

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 3

ER -